Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Richard Aldrich sold 31,236 shares of Concert Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $19.14, for a total transaction of $597,857.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Concert Pharmaceuticals Inc (CNCE) traded down $0.23 during midday trading on Friday, hitting $19.71. 515,100 shares of the stock traded hands, compared to its average volume of 743,733. Concert Pharmaceuticals Inc has a one year low of $8.61 and a one year high of $30.71. The stock has a market cap of $448.85, a PE ratio of 5.26 and a beta of 1.67.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. analysts predict that Concert Pharmaceuticals Inc will post 4.1 earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of Concert Pharmaceuticals during the 3rd quarter valued at $153,000. Alliancebernstein L.P. purchased a new stake in shares of Concert Pharmaceuticals during the 2nd quarter valued at $174,000. The Manufacturers Life Insurance Company grew its stake in shares of Concert Pharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock valued at $210,000 after buying an additional 287 shares during the period. Princeton Capital Management Inc. purchased a new stake in shares of Concert Pharmaceuticals during the 3rd quarter valued at $215,000. Finally, OxFORD Asset Management LLP grew its stake in shares of Concert Pharmaceuticals by 42.1% during the 2nd quarter. OxFORD Asset Management LLP now owns 19,711 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 5,835 shares during the period. 65.29% of the stock is owned by institutional investors.
Several research firms have commented on CNCE. BidaskClub cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine cut shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $27.00 target price on shares of Concert Pharmaceuticals in a research note on Friday, January 12th. Mizuho cut shares of Concert Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $23.00 target price for the company. in a research note on Friday, January 12th. Finally, TheStreet raised shares of Concert Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Monday, January 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $24.33.
COPYRIGHT VIOLATION NOTICE: “Concert Pharmaceuticals Inc (CNCE) Director Sells $597,857.04 in Stock” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.thestockobserver.com/2018/01/19/concert-pharmaceuticals-inc-cnce-director-sells-597857-04-in-stock.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.